Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development

Lisa M Reece; David Wc Beasley; Gregg N Milligan; Vanessa V Sarathy; Alan Dt Barrett

doi:10.1016/j.coviro.2018.03.005

Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development

Curr Opin Virol. 2018 Apr:29:72-78. doi: 10.1016/j.coviro.2018.03.005. Epub 2018 Apr 9.

Authors

Lisa M Reece¹, David Wc Beasley², Gregg N Milligan³, Vanessa V Sarathy⁴, Alan Dt Barrett⁵

Affiliations

¹ World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
² World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA; Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, USA.
³ World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.
⁴ Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
⁵ World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: abarrett@utmb.edu.

PMID: 29642053
DOI: 10.1016/j.coviro.2018.03.005

Abstract

Severe Fever with Thrombocytopenia Syndrome (SFTS) is a new emerging tick-borne disease caused by the phlebovirus, SFTS virus (SFTSV). The virus was discovered in central China in 2009 and has since been identified in both Japan and South Korea. Significant progress has been made on the molecular biology of the virus, and this has been used to develop diagnostic assays and reagents. Less progress has been made on the epidemiology, maintenance and transmission, clinical manifestations, immunological responses, and treatment regimens. A number of animal models have been investigated but, to date, none recapitulate all the clinical manifestations seen in humans. Vaccine development is at an early discovery phase.

Publication types

Review

MeSH terms

Animals
Disease Models, Animal
Host-Pathogen Interactions / immunology*
Humans
Immunity
Models, Molecular
Phlebotomus Fever / diagnosis
Phlebotomus Fever / epidemiology
Phlebotomus Fever / prevention & control*
Phlebotomus Fever / virology
Phlebovirus / classification
Phlebovirus / genetics
Phlebovirus / immunology*
Phylogeny
Protein Conformation
RNA, Viral
Viral Proteins / chemistry
Viral Proteins / genetics
Viral Vaccines / immunology*

Substances

RNA, Viral
Viral Proteins
Viral Vaccines

Supplementary concepts

SFTS phlebovirus